Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of [11C]-GSK2256098 in PAH
NCT02551653Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GSK2256098 in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GSK. Primary endpoints: Volume of Distribution of Radiolabeled GSK2256098 at Day 1 and Standardized Uptake Values of Radiolabeled GSK2256098 at Day 1. Started Nov 2015; status: completed.
02
Drugs
GSK2256098
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02551653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551653.